Adding ruxolitinib to pembrolizumab for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding a drug called ruxolitinib (which helps reduce inflammation) to the standard immunotherapy drug pembrolizumab is safe and effective for people with advanced head and neck cancer. It may help the immunotherapy work better, especially if you have a certain blood marker that suggests high inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer that has spread, come back, or is locally advanced and you are not able to have surgery or radiation for it.
- Your doctor plans to treat you with an immunotherapy drug called pembrolizumab (Keytruda).
- Your cancer cells have a protein called PD-L1 at a level of at least 1 (checked by a test).
- You are generally able to take care of yourself (up to being up and about more than half the day).
- You have a blood test result showing a high number of a certain type of white blood cell (called NLR) above 4 before starting pembrolizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial studies whether pembrolizumab plus chemotherapy (platinum and gemcitabine) can control recurrent or metastatic head and neck squamous cell carcinoma that can’t be cured with local treatments. It may help shrink tumors and slow disease growth in people who haven’t had cancer medicines for this stage before.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
Hear when a new Carcinoma, Squamous Cell of Head and Neck HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.